Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders
09. Januar 2023 07:00 ET
|
Lupin Ltd
Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables sustainable...
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®
09. Februar 2022 07:23 ET
|
Lupin Ltd
Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic...
Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
04. November 2021 08:31 ET
|
Lupin Ltd
FOR UK MEDICAL AND TRADE MEDIA ONLY Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 4...
Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
16. Februar 2021 02:00 ET
|
Lupin Ltd
Lupin responds to NICE Appraisal Consultation Document (ACD) on NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 16th February...
Scottish Medicines Consortium approves Lupin's NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)
08. Dezember 2020 04:00 ET
|
Lupin Ltd
Scottish Medicines Consortium approves NaMuscla® (mexiletine) to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough, UK, 8 December 2020: Lupin welcomes the...
US FDA Grants Mexiletine Orphan Drug Designation
08. Juni 2020 01:03 ET
|
Lupin Ltd
US FDA Grants Mexiletine Orphan Drug Designation Zug, Switzerland, 8 June 2019: Lupin is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)...
Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®
03. Juni 2020 01:00 ET
|
Lupin Ltd
Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®Enables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic...
Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
01. Februar 2019 05:04 ET
|
Lupin Ltd
Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 1 February 2019: Lupin is pleased to...
Lupin Limited: Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
08. Januar 2019 00:00 ET
|
Lupin Neurosciences Ltd
Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 8 January 2019: Lupin is pleased to announce that the...
Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
19. Oktober 2018 07:44 ET
|
Lupin Neurosciences Ltd
Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, October 19, 2018: Lupin Neurosciences, a...